Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Sendegobresib · CFT-8634

Small molecule (PROTAC degrader) · Degrader of bromodomain-containing protein 9 (BRD9)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Sendegobresib?

Sendegobresib is an orally bioavailable heterobifunctional protein degrader that binds BRD9, a component of one form of the BAF chromatin remodeling complex, and recruits the CRL4-CRBN E3 ubiquitin ligase to direct BRD9 for proteasomal degradation. It is being studied in synovial sarcoma and soft tissue sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CFT-8634
Drug type
Small molecule (PROTAC degrader)
Targets
bromodomain-containing protein 9 (BRD9), cereblon (CRBN) (binding partner it blocks)
Mechanism
Degrader of bromodomain-containing protein 9 (BRD9)
Pathways
CRL4-CRBN E3 ubiquitin ligase-mediated proteasomal degradation, BAF complex (non-canonical BAF) signaling
Therapy area
Oncology
In trials of
CCCC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
AW8PEP3VZ3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05355753 Phase 1 Synovial Sarcoma Terminated CCCC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Soft Tissue SarcomaSynovial Sarcoma

Other drugs acting on BRD9

FHD-609 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.